

## **STATEMENT ON PHARMACEUTICAL INDUSTRY CONTRIBUTIONS**

Cystic Fibrosis Canada receives funding from a number of corporations, including pharmaceutical companies. At this time, less than two per cent of Cystic Fibrosis Canada's revenue comes from pharmaceutical contributions. As noted in Cystic Fibrosis Canada's [Policy on Working with the Pharmaceutical and Medically-Related Products Industry](#), the funding that Cystic Fibrosis Canada receives from pharmaceutical companies is unrestricted and does not support our work to advocate for access to medications.

Over the past two years, Cystic Fibrosis Canada has received funding from:

AbbVie, AstraZeneca Canada Inc., Bayer Canada Inc., CREON, Gilead Sciences Inc., Horizon Pharmaceuticals, Merck Frosst Canada Inc., Mylan Pharmaceuticals ULC, Vertex Pharmaceuticals Inc.